Ebrahim Seyed Delpassand

20090087377, Apr 2, 2009

Mar 27, 2008

12/057066

Ali Azhdarinia - Houston TX, US
Ebrahim S. Delpassand - Houston TX, US
Izabela Tworowska - Houston TX, US

A61K 51/04
A61K 103/00
A61K 103/10
A61K 103/40
A61K 103/20
A61K 103/34
A61K 103/32
A61K 49/10
A61K 47/48

424 165, 424 9364, 514788

The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging.

20080247947, Oct 9, 2008

Apr 6, 2007

11/784251

Ebrahim S. Delpassand - Houston TX, US

A61K 51/08

424 169

A method for treating a neuroendocrine tumor is disclosed, which includes administering a first dose of In-pentetreotide to a subject having the neuroendocrine tumor; and administering a second dose of In-pentetreotide to the subject after a selected duration has elapsed after the administering of the first dose, wherein the first dose and the second dose are each about 400 mCi or higher, and wherein the selected duration is at least a week. In another method, the first dose and the second dose are each about 500 mCi and the selected duration is between 10 and 12 weeks. The method may further include administration of a third dose. A composition for treating a neuroendocrine tumor includes In-pentetreotide having a radioactivity of about 400 mCi or higher in a single dose.

20190336623, Nov 7, 2019

Jan 12, 2018

16/477623

- Houston TX, US
- COURBEVOIE, FR
Ebrahim S. DELPASSAND - Houston TX, US
Federico ROJAS-QUIJANO - Bedford TX, US
Paul JUREK - Red Oak TX, US
Garry E. KIEFER - Richardson TX, US
Tania A. STALLONS - Wylie TX, US
Amal SAIDI - Thomon-Les-Bains, FR
Julien TORGUE - Gaithersburg MD, US

A61K 51/08
A61K 51/04
A61P 35/00
A61K 47/22
A61K 47/12
A61K 47/10
A61K 47/18

A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination.

20160375157, Dec 29, 2016

Jun 28, 2016

15/195334

- Houston TX, US
Ebrahim S. DELPASSAND - Houston TX, US
Izabela TWOROWSKA - Houston TX, US

A61K 51/04
A61N 5/10
A61K 45/06

The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging.

20140228551, Aug 14, 2014

Jun 20, 2012

14/128347

Izabela Tworowska - Houston TX, US
Ebrahim S. Delpassand - Houston TX, US

RadioMedix Inc. - Houston TX

A61K 51/04
C07H 17/04
C07H 15/26

534 10, 536 53, 536 2911, 536 174

The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein the D02S derivatives having the following structure: wherein R′, R′ are each independently —OH or —O-alkyl; Ris a hydrogen, a linker, or a ligand; Ris a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety.